CONCEPT MEDICAL GROUP RECOGNIZED AMONG INDIA’S TOP 30 MID-SIZE BEST WORKPLACES IN MANUFACTURING 2026

From manufacturing floors and R&D labs to quality, regulatory affairs, operations, sales, and corporate support functions, employees across Concept Medical Group have contributed to shaping a culture defined by integrity, continuous improvement, and shared success. The Group believes that sustainable innovation in healthcare starts with empowered and engaged teams.

“At Concept Medical Group, we believe great products are built by great teams,” said Parth Doshi, Executive Director. “This recognition reflects the ownership mindset and collaborative spirit our people demonstrate every day. As we continue to expand globally, we remain committed to strengthening a culture that encourages ideas, rewards accountability, and enables every individual to perform at their best, while staying aligned to our shared purpose.”

Guided by the philosophy of “One Team. One Goal,” Concept Medical Group has consistently invested in an environment where employees feel heard, trusted, and motivated to contribute meaningfully. This culture continues to be a key enabler of the Group’s momentum, supporting manufacturing excellence, accelerating innovation, and ultimately advancing patient outcomes across global markets.

As the organization continues its journey of growth, this recognition serves as both a moment of pride and a renewed commitment: to raise the bar in manufacturing and healthcare innovation, while building a workplace where people can thrive, learn, and lead.

About Concept Medical Group

Concept Medical Group is a global medical technology group advancing coronary and peripheral vascular care through patented, nanocarrier-based drug‑delivery platforms. Headquartered in Tampa, Florida, the Group pioneered MagicTouch the world’s first commercially available sirolimus‑coated balloon (SCB) built on the proprietary Nanolute platform and offers a growing portfolio of drug‑coated balloons and polymer‑free drug‑eluting stents. With a commercial presence in 80+ countries, its technologies have treated more than one million patients worldwide. Concept Medical’s evidence base spans 45+ clinical trials involving 24,000+ patients, including completed studies in Japan; MagicTouch holds CE Mark approval, U.S. FDA Breakthrough Device Designation, and five U.S. FDA IDE approvals across coronary and peripheral indications. Envision Scientific, the Group’s large‑scale manufacturing platform in India, is ESG‑certified, IGBC Gold‑rated and ISO‑certified, operates under systems compliant with key global regulators including PMDA (Japan), and has the capacity to produce over one million drug‑delivery devices annually. The Group is committed to expanding indications and improving outcomes for patients globally.

If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.